2025-12-06 - Analysis Report
Here's a breakdown of the provided information for Recursion Pharmaceuticals (RXRX), along with an analysis:

**0) Summary of Data**

*   **Company:** Recursion Pharmaceuticals Inc.
*   **Return vs. S&P 500 (VOO):** RXRX underperforming significantly.
*   **Stock Price:** Current price slightly below recent averages.
*   **Market Risk Indicator:** Medium Investment
*   **Hybrid Signal:** Buy 100% with MRI 0.9
*   **News:** Mixed, including meme stock status, earnings miss, and AI potential.
*   **Analyst Ratings:** Target Price (avg/high/low): 6.33 / 10.00 / 3.00
*   **Earnings:** Consistent losses.
*   **Financials:** Negative profit margins, fluctuating revenue, and negative ROE.

**1) Return Comparison**

*   **Company Overview:** Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging AI and machine learning to discover and develop novel therapeutics.
*   **Return Performance:** RXRX's cumulative return is -24.55%, significantly underperforming the S&P 500 (VOO) at 43.26%.
*   **Divergence:** The current divergence is -69.5, with a relative divergence of 2.7.  This means the stock is near its lowest divergence point compared to the S&P 500 in the observed period.  It is currently underperforming significantly.
*   **Alpha, Beta Analysis:**

    *   **CAGR:** Variable year-over-year performance with high volatility.
    *   **MDD:** Very high Maximum Drawdown values (around 80%), indicating substantial risk.
    *   **Alpha:** Fluctuating alpha; negative in recent periods, indicating underperformance relative to the market.
    *   **Beta:** Low Beta values suggest the stock is not strongly correlated with the overall market.
    *   **Cap:** The capitalization has been consistently decreasing since 2021-2023, suggesting challenges.

**Analysis:** RXRX has significantly underperformed the S&P 500. The high MDD and negative Alpha in recent periods highlight the substantial risk associated with this stock. Decreasing capitalization also causes concern.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** $4.66
*   **Last Market Data:** Price of 4.775, with a negative change of -2.95% compared to the previous close. This indicates a recent drop.
*   **Moving Averages:**
    *   5-day SMA: 4.512
    *   20-day SMA: 4.4065
    *   60-day SMA: 5.0772

**Analysis:** The stock price is currently above its 5-day and 20-day moving averages, suggesting a short-term upward trend. However, it's still below the 60-day moving average, indicating the longer-term trend may still be downward. The recent price drop (-2.95%) indicates some recent volatility.

**3) Technical Indicators**

*   **MRI:** 0.8 (Medium Investment).
*   **RSI:** 50.24.  A neutral reading, suggesting neither overbought nor oversold conditions.
*   **PPO:** 1.52. Positive, suggesting that a short-term moving average is trending higher than a longer-term moving average, possibly indicating an uptrend.
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (225 shares - Very Safe - MRI:0.90). This signals to buy 100% of the investment with MRI 0.9.
*   **Recent Divergence Change:** Short-term increase (+1.9) in relative divergence, suggesting a short-term price increase.
*   **Expected Return:** A very negative expected return of -180.9%.

**Analysis:** The signals are mixed. While the MRI suggests a medium investment and the divergence and PPO indicate a possible short-term upward trend, the extremely negative expected return is a major concern.

**4) Recent News & Significant Events**

*   **[2025-11-19] Is Recursion Pharmaceuticals a Meme Stock?** - This raises concerns about the stock's valuation being driven by social media trends rather than fundamentals.
*   **[2025-11-21] Recursion Pharmaceuticals Stock (RXRX) Opinions on Q3 Earnings Miss** - Confirms recent poor financial performance.
*   **[2025-12-05] Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue?** - This might be linked to short-term speculation.
*   **[2025-12-05] Jim Cramer: This Health Care Stock Has Been 'Horrendous'** - Negative sentiment from a prominent market commentator.
*   **[2025-12-04] Will RXRX stock benefit from AI adoption** - Highlights the potential future, but the current reality might not be as promising.
*   **[2025-11-02] Recursion Pharmaceuticals (RXRX) Stock: CEO Sells $5.8 Million in Shares Following Exscientia Merger** - Insider selling can be a negative signal.

**Analysis:** The news flow is a mixed bag, but with more negative signals than positive ones.

**4-2) Analyst Opinions**

*   **Consensus:** No key assigned, indicating a lack of strong consensus.
*   **Target Price:** Average target of $6.33, with a wide range ($3.00 - $10.00) suggesting high uncertainty.

**Analysis:** Analyst opinions appear to be neutral to slightly positive, but there's significant disagreement among analysts, reflecting the high-risk, high-reward nature of the stock.

**5) Recent Earnings Analysis**

| Date       | EPS   | Revenue      |
| ---------- | ----- | ------------- |
| 2025-11-05 | -0.36 | 0.01 B$      |
| 2025-08-05 | -0.41 | 0.02 B$      |
| 2025-05-05 | -0.5  | 0.01 B$      |
| 2024-11-06 | -0.34 | 0.03 B$      |
| 2025-11-05 | -0.34 | 0.03 B$      |

**Analysis:** Earnings reports consistently show negative EPS and relatively low revenue, indicating the company is struggling to achieve profitability. The EPS has been improving, but this is only a marginal movement at this stage.

**6) Financial Information**

| Quarter    | Revenue   | Profit Margin |
| ---------- | --------- | ------------- |
| 2025-09-30 | $0.00B   | -194.74%      |
| 2025-06-30 | $0.02B   | -5.54%       |
| 2025-03-31 | $0.01B   | -47.31%       |
| 2024-12-31 | $0.00B   | -183.62%      |
| 2024-09-30 | $0.03B   | 53.69%        |

| Quarter    | Equity    | ROE       |
| ---------- | --------- | --------- |
| 2025-09-30 | $1.05B   | -15.50%   |
| 2025-06-30 | $0.92B   | -18.70%   |
| 2025-03-31 | $0.93B   | -21.68%   |
| 2024-12-31 | $1.03B   | -17.29%   |
| 2024-09-30 | $0.52B   | -18.27%   |

**Analysis:** The financial data shows significant challenges. Revenue is inconsistent, and profit margins are mostly negative, indicating the company is losing money on its sales. While the equity position is relatively strong, the negative ROE suggests the company is not effectively using its equity to generate profits.

**7) Comprehensive Analysis**

Recursion Pharmaceuticals (RXRX) presents a high-risk, high-reward investment opportunity. The company is underperforming the S&P 500 significantly, with a very negative expected return. While there are short-term signals of potential upward movement, the long-term trends and financial data point to ongoing challenges. The company is not profitable, and its revenue stream is inconsistent. The stock's valuation may also be influenced by social media trends, adding to the risk.

**Recommendation:** While the AI technology and the potential for future growth are appealing, the current financial situation and market sentiment suggest caution. The MRI (Market Risk Indicator) shows a recommendation as a Medium Investment, but I would highly suggest investors carefully consider their risk tolerance and conduct thorough due diligence before investing in RXRX. Monitor the company's progress in achieving profitability and generating consistent revenue.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.